Cargando…

Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation

Modulation of the innate immune system is emerging as a promising therapeutic strategy against Alzheimer's disease (AD). However, determinants of a beneficial therapeutic effect are ill-understood. Thus, we investigated the potential of 18 kDa translocator protein positron-emission-tomography (...

Descripción completa

Detalles Bibliográficos
Autores principales: Biechele, Gloria, Blume, Tanja, Deussing, Maximilian, Zott, Benedikt, Shi, Yuan, Xiang, Xianyuan, Franzmeier, Nicolai, Kleinberger, Gernot, Peters, Finn, Ochs, Katharina, Focke, Carola, Sacher, Christian, Wind, Karin, Schmidt, Claudio, Lindner, Simon, Gildehaus, Franz-Josef, Eckenweber, Florian, Beyer, Leonie, von Ungern-Sternberg, Barbara, Bartenstein, Peter, Baumann, Karlheinz, Dorostkar, Mario M., Rominger, Axel, Cumming, Paul, Willem, Michael, Adelsberger, Helmuth, Herms, Jochen, Brendel, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419052/
https://www.ncbi.nlm.nih.gov/pubmed/34522221
http://dx.doi.org/10.7150/thno.64022
_version_ 1783748679136444416
author Biechele, Gloria
Blume, Tanja
Deussing, Maximilian
Zott, Benedikt
Shi, Yuan
Xiang, Xianyuan
Franzmeier, Nicolai
Kleinberger, Gernot
Peters, Finn
Ochs, Katharina
Focke, Carola
Sacher, Christian
Wind, Karin
Schmidt, Claudio
Lindner, Simon
Gildehaus, Franz-Josef
Eckenweber, Florian
Beyer, Leonie
von Ungern-Sternberg, Barbara
Bartenstein, Peter
Baumann, Karlheinz
Dorostkar, Mario M.
Rominger, Axel
Cumming, Paul
Willem, Michael
Adelsberger, Helmuth
Herms, Jochen
Brendel, Matthias
author_facet Biechele, Gloria
Blume, Tanja
Deussing, Maximilian
Zott, Benedikt
Shi, Yuan
Xiang, Xianyuan
Franzmeier, Nicolai
Kleinberger, Gernot
Peters, Finn
Ochs, Katharina
Focke, Carola
Sacher, Christian
Wind, Karin
Schmidt, Claudio
Lindner, Simon
Gildehaus, Franz-Josef
Eckenweber, Florian
Beyer, Leonie
von Ungern-Sternberg, Barbara
Bartenstein, Peter
Baumann, Karlheinz
Dorostkar, Mario M.
Rominger, Axel
Cumming, Paul
Willem, Michael
Adelsberger, Helmuth
Herms, Jochen
Brendel, Matthias
author_sort Biechele, Gloria
collection PubMed
description Modulation of the innate immune system is emerging as a promising therapeutic strategy against Alzheimer's disease (AD). However, determinants of a beneficial therapeutic effect are ill-understood. Thus, we investigated the potential of 18 kDa translocator protein positron-emission-tomography (TSPO-PET) for assessment of microglial activation in mouse brain before and during chronic immunomodulation. Methods: Serial TSPO-PET was performed during five months of chronic microglia modulation by stimulation of the peroxisome proliferator-activated receptor (PPAR)-γ with pioglitazone in two different mouse models of AD (PS2APP, App(NL-G-F)). Using mixed statistical models on longitudinal TSPO-PET data, we tested for effects of therapy and sex on treatment response. We tested correlations of baseline with longitudinal measures of TSPO-PET, and correlations between PET results with spatial learning performance and β-amyloid accumulation of individual mice. Immunohistochemistry was used to determine the molecular source of the TSPO-PET signal. Results: Pioglitazone-treated female PS2APP and App(NL-G-F) mice showed attenuation of the longitudinal increases in TSPO-PET signal when compared to vehicle controls, whereas treated male App(NL-G-F) mice showed the opposite effect. Baseline TSPO-PET strongly predicted changes in microglial activation in treated mice (R = -0.874, p < 0.0001) but not in vehicle controls (R = -0.356, p = 0.081). Reduced TSPO-PET signal upon pharmacological treatment was associated with better spatial learning despite higher fibrillar β-amyloid accumulation. Immunohistochemistry confirmed activated microglia to be the source of the TSPO-PET signal (R = 0.952, p < 0.0001). Conclusion: TSPO-PET represents a sensitive biomarker for monitoring of immunomodulation and closely reflects activated microglia. Sex and pre-therapeutic assessment of baseline microglial activation predict individual immunomodulation effects and may serve for responder stratification.
format Online
Article
Text
id pubmed-8419052
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-84190522021-09-13 Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation Biechele, Gloria Blume, Tanja Deussing, Maximilian Zott, Benedikt Shi, Yuan Xiang, Xianyuan Franzmeier, Nicolai Kleinberger, Gernot Peters, Finn Ochs, Katharina Focke, Carola Sacher, Christian Wind, Karin Schmidt, Claudio Lindner, Simon Gildehaus, Franz-Josef Eckenweber, Florian Beyer, Leonie von Ungern-Sternberg, Barbara Bartenstein, Peter Baumann, Karlheinz Dorostkar, Mario M. Rominger, Axel Cumming, Paul Willem, Michael Adelsberger, Helmuth Herms, Jochen Brendel, Matthias Theranostics Research Paper Modulation of the innate immune system is emerging as a promising therapeutic strategy against Alzheimer's disease (AD). However, determinants of a beneficial therapeutic effect are ill-understood. Thus, we investigated the potential of 18 kDa translocator protein positron-emission-tomography (TSPO-PET) for assessment of microglial activation in mouse brain before and during chronic immunomodulation. Methods: Serial TSPO-PET was performed during five months of chronic microglia modulation by stimulation of the peroxisome proliferator-activated receptor (PPAR)-γ with pioglitazone in two different mouse models of AD (PS2APP, App(NL-G-F)). Using mixed statistical models on longitudinal TSPO-PET data, we tested for effects of therapy and sex on treatment response. We tested correlations of baseline with longitudinal measures of TSPO-PET, and correlations between PET results with spatial learning performance and β-amyloid accumulation of individual mice. Immunohistochemistry was used to determine the molecular source of the TSPO-PET signal. Results: Pioglitazone-treated female PS2APP and App(NL-G-F) mice showed attenuation of the longitudinal increases in TSPO-PET signal when compared to vehicle controls, whereas treated male App(NL-G-F) mice showed the opposite effect. Baseline TSPO-PET strongly predicted changes in microglial activation in treated mice (R = -0.874, p < 0.0001) but not in vehicle controls (R = -0.356, p = 0.081). Reduced TSPO-PET signal upon pharmacological treatment was associated with better spatial learning despite higher fibrillar β-amyloid accumulation. Immunohistochemistry confirmed activated microglia to be the source of the TSPO-PET signal (R = 0.952, p < 0.0001). Conclusion: TSPO-PET represents a sensitive biomarker for monitoring of immunomodulation and closely reflects activated microglia. Sex and pre-therapeutic assessment of baseline microglial activation predict individual immunomodulation effects and may serve for responder stratification. Ivyspring International Publisher 2021-08-19 /pmc/articles/PMC8419052/ /pubmed/34522221 http://dx.doi.org/10.7150/thno.64022 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Biechele, Gloria
Blume, Tanja
Deussing, Maximilian
Zott, Benedikt
Shi, Yuan
Xiang, Xianyuan
Franzmeier, Nicolai
Kleinberger, Gernot
Peters, Finn
Ochs, Katharina
Focke, Carola
Sacher, Christian
Wind, Karin
Schmidt, Claudio
Lindner, Simon
Gildehaus, Franz-Josef
Eckenweber, Florian
Beyer, Leonie
von Ungern-Sternberg, Barbara
Bartenstein, Peter
Baumann, Karlheinz
Dorostkar, Mario M.
Rominger, Axel
Cumming, Paul
Willem, Michael
Adelsberger, Helmuth
Herms, Jochen
Brendel, Matthias
Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation
title Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation
title_full Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation
title_fullStr Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation
title_full_unstemmed Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation
title_short Pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation
title_sort pre-therapeutic microglia activation and sex determine therapy effects of chronic immunomodulation
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419052/
https://www.ncbi.nlm.nih.gov/pubmed/34522221
http://dx.doi.org/10.7150/thno.64022
work_keys_str_mv AT biechelegloria pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT blumetanja pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT deussingmaximilian pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT zottbenedikt pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT shiyuan pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT xiangxianyuan pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT franzmeiernicolai pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT kleinbergergernot pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT petersfinn pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT ochskatharina pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT fockecarola pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT sacherchristian pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT windkarin pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT schmidtclaudio pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT lindnersimon pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT gildehausfranzjosef pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT eckenweberflorian pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT beyerleonie pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT vonungernsternbergbarbara pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT bartensteinpeter pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT baumannkarlheinz pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT dorostkarmariom pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT romingeraxel pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT cummingpaul pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT willemmichael pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT adelsbergerhelmuth pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT hermsjochen pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation
AT brendelmatthias pretherapeuticmicrogliaactivationandsexdeterminetherapyeffectsofchronicimmunomodulation